2010-19: Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures
Investigator Initiated Research
Inclusion open since 24-4-2012
The rate of progression of diabetic retinopathy varies widely between different patients, even with similar metabolic control [Cunha-Vaz, Prog Retin. Eye Res. 2005]. It is becoming clear that a large percentage of patients with mild NPDR will take a long time to develop any sight-threatening complication. The inclusion of eyes/patients in a clinical trial that do not show any significant worsening during the period of the trial masks any beneficial effect of the drug being tested. It appears that the only option is to identify the eyes/patients that show progression of retinopathy during a pre-trial run-in period and only include such patients. Characterization of progressor phenotypes in the early stages of diabetic retinopathy and identification of biomarkers of disease progression are also objectives of major interest. This is an observational, prospective study to identify eyes that show worsening and disease progression (progressor phenotypes).